Abstract
The COVID-19 pandemic generated significant cardiovascular complications in critically ill patients, particularly in those with angina pectoris, increasing morbidity, mortality, and therapeutic complexity in Intensive Care Units. The coexistence of systemic inflammation, endothelial damage, and polypharmacy promoted the occurrence of adverse drug events (ADEs), highlighting the need for standardized and scientifically validated clinical protocols. The objective of this study was to validate, through the Delphi method, a therapeutic algorithm for patients with COVID-19 and angina pectoris at the Hospital General Docente Ambato. A mixed-method, descriptive-propositional study with a retrospective, analytical, and cross-sectional design was conducted. The population consisted of 1,392 medical records of critically ill patients admitted to the ICU between 2020 and 2022, from which a sample of 168 records was selected through simple random sampling. Pharmacological regimens, incidence of ADEs, and clinical severity scales were analyzed using KDIGO criteria and Hy’s Law for the detection of organ toxicity. Validation of the therapeutic algorithm was carried out through two Delphi rounds with experts in critical care, cardiology, and infectious diseases. The results showed favorable consensus regarding the clinical usefulness, pharmacological safety, and institutional applicability of the algorithm. It is concluded that Delphi-based validation strengthens therapeutic standardization, optimizes pharmacovigilance, and improves clinical decision-making in critically ill patients with COVID-19 and angina pectoris.